Seagen Inc.

Philip Moquist

Anusuya Choudhury

Wendel William Doubleday

Yunyu Mao

Svetlana Doronina

Compounds and compositions are disclosed in which a Drug Unit is linked to a targeting Ligand Unit through a self-stabilizing Linker Unit from which a drug compound or active drug moiety is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as cancer or an autoimmune disease using the compounds and compositions of the invention are also disclosed.

Drug conjugates with self-stabilizing linkers having improved physiochemical properties

Ligand Drug Conjugates of hydrophobically-modified auristatin F compounds that exhibit cytotoxic activities towards targeted cells, including abnormal cells such as cancer cells, that are MDR+ while also exhibiting bystander activities towards nearby cells having lower expression of the moeity targeted by the Conjugate.

Hydrophobic Auristatin F compounds and conjugates thereof

The present invention provides improved processes for the preparation of auristatin drug-linkers with a PEG unit, as well as intermediates thereof.

Process for the preparation of pegylated drug-linkers and intermediates thereof

The present invention provides improved processes for the preparation of drug-linkers with a &#x3b2;-glucuronide cleavable unit, as well as intermediates thereof.

Growing community of inventors

Seattle, WA, United States of America

Philip Moquist